Fibroblast growth factor-9 enhances M2 macrophage differentiation and attenuates adverse cardiac remodeling in the infarcted diabetic heart

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Singla, Dinender K ^a   Singla, Reetu D ^a   Abdelli, Latifa S ^a   Glass, Carley ^a  

^a UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 9; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; FGF9 PROTEIN, MOUSE; PRIMER DNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIAC REMODELING; CELL DIFFERENTIATION; CELL INFILTRATION; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DIABETES MELLITUS; DRUG EFFECT; FEMALE; HEART CONTRACTION; HEART DISEASE; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE FIBROSIS; HEART PROTECTION; MACROPHAGE; MALE; MONOCYTE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; ANALYSIS OF VARIANCE; ANIMAL; CYTOLOGY; ECHOCARDIOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; HEART ATRIUM REMODELING; HEART FUNCTION TEST; IMMUNOHISTOCHEMISTRY; METABOLISM; NONOBESE DIABETIC MOUSE; PATHOPHYSIOLOGY; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALIA; MUS;

ANALYSIS OF VARIANCE; ANIMALS; ATRIAL REMODELING; CELL DIFFERENTIATION; CYTOKINES; DIABETES COMPLICATIONS; DNA PRIMERS; ECHOCARDIOGRAPHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBROBLAST GROWTH FACTOR 9; HEART FUNCTION TESTS; IMMUNOHISTOCHEMISTRY; MACROPHAGES; MICE; MICE, INBRED NOD; MONOCYTES; MYOCARDIAL INFARCTION; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84929466749     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0120739     Document Type: Article

References (37)

1. Paneni F, Beckman JA, Creager MA, Cosentino F. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Eur Heart J. 2013;34:2436-2443. doi: 10.1093/eurheartj/eht149 PMID: 23641007
2. Tarr JM, Kaul K, Chopra M, Kohner EM, Chibber R. Pathophysiology of diabetic retinopathy. ISRN Ophthalmol. 2013;2013:343560. doi: 10.1155/2013/343560 PMID: 24563789
3. Duran-Salgado MB, Rubio-Guerra AF. Diabetic nephropathy and inflammation. World J Diabetes. 2014;5:393-398. doi: 10.4239/wjd.v5.i3.393 PMID: 24936261
4. Sytze Van Dam P, Cotter MA, Bravenboer B, Cameron NE. Pathogenesis of diabetic neuropathy: focus on neurovascular mechanisms. Eur J Pharmacol. 2013;719:180-186. doi: 10.1016/j.ejphar.2013.07. 017 PMID: 23872412
5. Ehses JA, Perren A, Eppler E, Ribaux P, Pospisilik JA, Maor-Cahn R, et al. Increased number of isletassociated macrophages in type 2 diabetes. Diabetes. 2007;56:2356-2370. PMID: 17579207
6. Mirza R, Koh TJ. Dysregulation of monocyte/macrophage phenotype in wounds of diabetic mice. Cytokine. 2011;56:256-264. doi: 10.1016/j.cyto.2011.06.016 PMID: 21803601
7. Meng L, Park J, Cai Q, Lanting L, Reddy MA, Natarajan R. Diabetic conditions promote binding of monocytes to vascular smooth muscle cells and their subsequent differentiation. Am J Physiol Heart Circ Physiol. 2010;298:H736-745. doi: 10.1152/ajpheart.00935.2009 PMID: 20008269
8. Li SL, Reddy MA, Cai Q, Meng L, Yuan H, Lanting L, et al. Enhanced proatherogenic responses in macrophages and vascular smooth muscle cells derived from diabetic db/db mice. Diabetes. 2006;55:2611-2619. PMID: 16936211
9. Laskin DL, Pendino KJ. Macrophages and inflammatory mediators in tissue injury. Annu Rev Pharmacol Toxicol. 1995;35:655-677. PMID: 7598511
10. Leavy O. Immunotherapy: Stopping monocytes in their tracks. Nat Rev Immunol. 2011;11:715. doi: 10.1038/nri3096 PMID: 22025043
11. Anzai A, Anzai T, Nagai S, Maekawa Y, Naito K, Kaneko H, et al. Regulatory role of dendritic cells in postinfarction healing and left ventricular remodeling. Circulation. 2012;125:1234-1245. doi: 10.1161/CIRCULATIONAHA.111.052126 PMID: 22308302
12. Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov. 2009;8:235-253. doi: 10.1038/nrd2792 PMID: 19247306
13. Itoh N, Ornitz DM. Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease. J Biochem. 2011;149:121-130. doi: 10.1093/jb/mvq121 PMID: 20940169
14. Hecht D, Zimmerman N, Bedford M, Avivi A, Yayon A. Identification of fibroblast growth factor 9 (FGF9) as a high affinity, heparin dependent ligand for FGF receptors 3 and 2 but not for FGF receptors 1 and 4. Growth Factors. 1995;12:223-233. PMID: 8619928
15. Frontini MJ, Nong Z, Gros R, Drangova M, O'Neil C, Rahman MN, et al. Fibroblast growth factor 9 delivery during angiogenesis produces durable, vasoresponsive microvessels wrapped by smooth muscle cells. Nat Biotechnol. 2011;29:421-427. doi: 10.1038/nbt.1845 PMID: 21499246
16. Gay D, Kwon O, Zhang Z, Spata M, Plikus MV, Holler PD, et al. Fgf9 from dermal gammadelta T cells induces hair follicle neogenesis after wounding. Nat Med. 2013;19:916-923. doi: 10.1038/nm.3181 PMID: 23727932
17. Pirvola U, Zhang X, Mantela J, Ornitz DM, Ylikoski J. Fgf9 signaling regulates inner ear morphogenesis through epithelial-mesenchymal interactions. Dev Biol. 2004;273:350-360. PMID: 15328018
18. Lin Y, Chen L, Lin C, Luo Y, Tsai RY, Wang F. Neuron-derived FGF9 is essential for scaffold formation of Bergmann radial fibers and migration of granule neurons in the cerebellum. Dev Biol. 2009;329:44-54. doi: 10.1016/j.ydbio.2009.02.011 PMID: 19232523
19. Harada M, Murakami H, Okawa A, Okimoto N, Hiraoka S, Nakahara T, et al. FGF9 monomer-dimer equilibrium regulates extracellular matrix affinity and tissue diffusion. Nat Genet. 2009;41:289-298. doi: 10.1038/ng.316 PMID: 19219044
20. Colvin JS, Green RP, Schmahl J, Capel B, Ornitz DM. Male-to-female sex reversal in mice lacking fibroblast growth factor 9. Cell. 2001;104:875-889. PMID: 11290325
21. Korf-Klingebiel M, Kempf T, Schluter KD, Willenbockel C, Brod T, Heineke J, et al. Conditional transgenic expression of fibroblast growth factor 9 in the adult mouse heart reduces heart failure mortality after myocardial infarction. Circulation. 2011;123:504-514. doi: 10.1161/CIRCULATIONAHA.110. 989665 PMID: 21262993
22. Glass C, Singla DK. Overexpression of TIMP-1 in embryonic stem cells attenuates adverse cardiac remodeling following myocardial infarction. Cell Transplant. 2012;21:1931-1944. doi: 10.3727/096368911X627561 PMID: 22449760
23. Kumar D, Hacker TA, Buck J, Whitesell LF, Kaji EH, Douglas PS, et al. Distinct mouse coronary anatomy and myocardial infarction consequent to ligation. Coron Artery Dis. 2005;16:41-44. PMID: 15654199
24. Singla DK, Long X, Glass C, Singla RD, Yan B. Induced pluripotent stem (iPS) cells repair and regenerate infarcted myocardium. Mol Pharm. 2011;8:1573-1581. doi: 10.1021/mp2001704 PMID: 21542647
25. Glass C, Singla DK. MicroRNA-1 transfected embryonic stem cells enhance cardiac myocyte differentiation and inhibit apoptosis by modulating the PTEN/Akt pathway in the infarcted heart. Am J Physiol Heart Circ Physiol. 2011;301:H2038-2049. doi: 10.1152/ajpheart.00271.2011 PMID: 21856911
26. Italiani P, Boraschi D. From Monocytes to M1/M2 Macrophages: Phenotypical vs. Functional Differentiation. Front Immunol. 2014;5:514. doi: 10.3389/fimmu.2014.00514 PMID: 25368618
27. Laskin DL. Macrophages and inflammatory mediators in chemical toxicity: a battle of forces. Chem Res Toxicol. 2009;22:1376-1385. doi: 10.1021/tx900086v PMID: 19645497
28. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004;25:677-686. PMID: 15530839
29. Van Der Laan AM, Nahrendorf M, Piek JJ. Healing and adverse remodelling after acute myocardial infarction: role of the cellular immune response. Heart. 2012;98:1384-1390. doi: 10.1136/heartjnl-2012-301623 PMID: 22904145
30. Kumar D, Jugdutt BI. Apoptosis and oxidants in the heart. J Lab Clin Med. 2003;142:288-297. PMID: 14647032
31. Laskin DL, Sunil VR, Gardner CR, Laskin JD. Macrophages and tissue injury: agents of defense or destruction? Annu Rev Pharmacol Toxicol. 2011;51:267-288. doi: 10.1146/annurev. pharmtox.010909. 105812 PMID: 20887196
32. Bardini G, Dicembrini I, Cresci B, Rotella CM. Inflammation markers and metabolic characteristics of subjects with 1-h plasma glucose levels. Diabetes Care. 2010;33:411-413. doi: 10.2337/dc09-1342 PMID: 19918010
33. Muller S, Martin S, Koenig W, Hanifi-Moghaddam P, Rathmann W, Haastert B, et al. Impaired glucose tolerance is associated with increased serum concentrations of interleukin 6 and co-regulated acutephase proteins but not TNF-alpha or its receptors. Diabetologia. 2002;45:805-812. PMID: 12107724
34. Pickup JC, Chusney GD, Thomas SM, Burt D. Plasma interleukin-6, tumour necrosis factor alpha and blood cytokine production in type 2 diabetes. Life Sci. 2000;67:291-300. PMID: 10983873
35. Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res. 2002;53:31-47. PMID: 11744011
36. Nahrendorf M, Pittet MJ, Swirski FK. Monocytes: protagonists of infarct inflammation and repair after myocardial infarction. Circulation. 2010;121:2437-2445. doi: 10.1161/CIRCULATIONAHA.109. 916346 PMID: 20530020
37. Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell. 2011;145:341-355. doi: 10.1016/j.cell.2011.04.005 PMID: 21529710